Therapeutic resistance of breast cancer stem cells and its related signaling pathway

doi:10.3760/cma.j.issn.1673-422X.2017.07.017

Journal of International Oncology ›› 2017, Vol. 44 ›› Issue (7): 544-546.doi: 10.3760/cma.j.issn.1673-422X.2017.07.017

Previous Articles Next Articles

Therapeutic resistance of breast cancer stem cells and its related signaling pathway

Tong Yalan, Han Tao, Liu Zhongzheng, Yuan Gang, Liang Yan, Liu Zhaozhe, Xie Xiaodong, Yue Chengshan

Department of Radiation Oncology, Hanzhong Central Hospital of Shaanxi Province, Hanzhong 723000, China

Received:2016-12-13 Online:2017-07-08 Published:2017-06-20
Contact: Yue Chengshan E-mail:yuechs@163.com
Supported by:
Postdoctoral Science Foundation of China (2015M582822)

Abstract

Abstract: Breast cancer stem cells (CSCs) are the main causes leading to the failure of treatment of breast cancer and play important roles in the progression of breast cancer and drug resistance, which are closely related to the therapeutic resistance of radiotherapy and chemotherapy, and endocrine therapy. The metastatic potential and therapeutic resistance of CSCs are associated with epithelial mesenchymal transition and Hedgehog, Wnt, interleukin6/signal transduction and tanscriptional activation factor 3, transforming growth factorβ and other signaling pathways. While some of the targeted drugs targeting these signaling pathways are undergoing clinical transformation, which is expected to provide new approach for the clinical treatment of breast cancer.

Tong Yalan, Han Tao, Liu Zhongzheng, Yuan Gang, Liang Yan, Liu Zhaozhe, Xie Xiaodong, Yue Chengshan. Therapeutic resistance of breast cancer stem cells and its related signaling pathway[J]. Journal of International Oncology, 2017, 44(7): 544-546.

References

［1］ Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?［J］. Cell Stem Cell, 2015, 16(3): 225-238. DOI: 10.1016/j.stem.2015.02.015. ［2］ AIHajj M, Wicha MS, BenitoHernandez A, et al. Prospective identification of tumorigenic breast cancer cells［J］. Proc Natl Acad Sci USA, 2003, 100(7): 3983-3988. DOI: 10.1073/pnas.0530291100. ［3］ Liu Y, Nenutil R, Appleyard MV, et al. Lack of correlation of stem cell markers in breast cancer stem cells［J］. Br J Cancer, 2014, 110(8): 2063-2071. DOI: 10.1038/bjc.2014.105. ［4］ CharafeJauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 1positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer［J］. Clin Cancer Res, 2010, 16(1): 45-55. DOI: 10.1158/1078-0432.CCR-09-1630. ［5］ McDermott SP, Wicha MS. Targeting breast cancer stem cells［J］. Mol Oncol, 2010, 4(5): 404-419. DOI: 10.1016/j.molonc.2010.06.005. ［6］ Wei W, Tweardy DJ, Zhang M, et al. STAT3 signaling is activated preferentially in tumorinitiating cells in claudinlow models of human breast cancer［J］. Stem Cells, 2014, 32(10): 2571-2582. DOI: 10.1002/stem.1752. ［7］ Wei W, Lewis MT. Identifying and targeting tumorinitiating cells in the treatment of breast cancer［J］. Endocr Relat Cancer, 2015, 22(3): R135-155. DOI: 10.1530/ERC-14-0447. ［8］ Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stemlike cells that selfrenew, give rise to phenotypically diverse progeny and survive chemotherapy［J］. Breast Cancer Res, 2008, 10(2): R25. DOI: 10.1186/bcr1982. ［9］关心, 陆智祥, 杨同华. 肿瘤干细胞的生物学特性及其研究进展［J］. 生命科学, 2014, 26(2): 194200. ［10］ Zhang M, Atkinson RL, Rosen JM. Selective targeting of radiationresistant tumorinitiating cells［J］. Proc Natl Acad Sci USA, 2010, 107(8): 3522-3527. DOI: 10.1073/pnas.0910179107. ［11］ Howell A, Wardley AM. Overview of the impact of conventional systemic therapies on breast cancer［J］. Endocr Relat Cancer, 2005, 12 Suppl 1: S9-S16. DOI: 10.1677/erc.1.01003. ［12］ Dowsett M, Houghton J, Iden C, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status［J］. Ann Oncol, 2006, 17(5): 818-826. DOI: 10.1093/annonc/mdl016. ［13］ Haughian JM, Pinto MP, Harrell JC, et al. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch［J］. Proc Natl Acad Sci USA, 2012, 109(8): 2742-2747. DOI: 10.1073/pnas.1106509108. ［14］ Chakrabarty A, Bhola NE, Sutton C, et al. Trastuzumabresistant cells rely on a HER2PI3KFoxOsurvivin axis and are sensitive to PI3K inhibitors［J］. Cancer Res, 2013, 73(3): 1190-1200. DOI: 10.1158/00085472.CAN-12-2440. ［15］ Bakrania AK, Variya BC, Patel SS. Novel targets for paclitaxel nano formulations: hopes and hypes in triple negative breast cancer［J］. Pharmacol Res, 2016, 111: 577-591. DOI: 10.1016/j.phrs.2016.07.023. ［16］ Creighton CJ, Chang JC, Rosen JM. Epithelialmesenchymal transition (EMT) in tumorinitiating cells and its clinical implications in breast cancer［J］. J Mammary Gland Biol Neoplasia, 2010, 15(2): 253260. DOI: 10.1007/s1091101091731. ［17］ Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer［J］. Oncogene, 2010, 29(34): 4741-4751. DOI: 10.1038/onc.2010.215. ［18］ Onishi H, Katano M. Hedgehog signaling pathway as a therapeutic target in various types of cancer［J］. Cancer Sci, 2011, 102(10): 1756-1760. DOI: 10.1111/j.1349-7006.2011.02010.x. ［19］ Borah A, Raveendran S, Rochani A, et al. Targeting selfrenewal pathways in cancer stem cells: clinical implications for cancer therapy［J］. Oncogenesis, 2015, 4: e177. DOI: 10.1038/oncsis.2015.35. ［20］ O′Brien CA, Kreso A, Jamieson CH. Cancer stem cells and selfrenewal［J］. Clin Cancer Res, 2010, 16(12): 3113-3120. DOI: 10.1158/1078-0432.CCR-09-2824. ［21］ Yu H, Jove R. The STATs of cancernew molecular targets come of age［J］. Nat Rev Cancer, 2004, 4(2): 97-105. DOI: 10.1038/nrc1275. ［22］ Iliopoulos D, Hirsch HA, Wang G, et al. Inducible formation of breast cancer stem cells and their dynamic equilibrium with nonstem cancer cells via IL6 secretion［J］. Proc Natl Acad Sci USA, 2011, 108(4): 1397-1402. DOI: 10.1073/pnas.1018898108. ［23］ Thakur R, Trivedi R, Rastogi N, et al. Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer［J］. Sci Rep, 2015, 5: 10194. DOI: 10.1038/srep10194.

Therapeutic resistance of breast cancer stem cells and its related signaling pathway

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments